Cirrhosis of the Liver: MR Imaging with Mangafodipir Trisodium (Mn-DPDP) 1

Radiology

Volumn 198, Issue 2, 1996, Pages 567-572

  Murakami, Takamichi ^a,b   Baron, Richard L ^a   Federle, Michael P ^a   Peterson, Mark S ^a   Oliver III, James H ^a   Davis, Peter L ^a   Confer, Scharmen R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Liver neoplasms, diagnosis, 761.12143, 761.30, 761 794; Liver, cirrhosis, 761.12143, 761.30, 761 794; Liver, MR, 761.12143, 761.30, 761.794; Magnetic resonance (MR), contrast agents, 761.12143; Manganese, 761.12143

Indexed keywords

MANGAFODIPIR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER REGENERATION; LIVER TUMOR; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

CASE-CONTROL STUDIES; CONTRAST MEDIA; EDETIC ACID; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PYRIDOXAL PHOSPHATE;

EID: 0030068048     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.198.2.8596867     Document Type: Article

References (28)

1. Rocklage SM, Cacheris WP, Quay SC, Hahn FE, Raymond KN. Manganese (II) N,N′-dipyridoxylethylenediamine-N,N′-diacetate 5,5′-bis (phosphate): synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement. Inorg Chem 1989; 28:477-485.
2. Young SW, Simpson BB, Ratner AV, Matkin C, Carter EA. MRI measurement of hepatocyte toxicity using the new MRI contrast agent manganese dipyridoxal diphosphate, a manganese/pyridoxal 5-phosphate chelate. Magn Reson Med 1989; 10: 1-13
3. Elizondo G, Fretz CJ, Stark DD, et al. Preclinical evaluation of MnDPDP new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 1991; 178:73-78.
4. Lim KO, Stark DD, Leese PT, Pfefferbaum A, Rocklage SM, Quay SC. Hepatobiliary MR imaging: first human experience with MnDPDP. Radiology 1991; 178:79-82.
5. Bernardino ME, Young SW, Lee JKT, Weinreb JC. Contrast-enhanced magnetic resonance imaging of the liver with Mn-DPDP for known or suspected focal hepatic disease. Invest Radiol 1991; 26(suppl1):148-149.
6. Bernardino ME, Young SW, Lee JK, Weinreb JC. Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. Radiology 1992; 183:53-58
7. Hamm B, Vogl TJ, Branding G, et al. Focal liver lesions. MR imaging with Mn-DPDP - initial clinical results in 40 patients. Radiology 1992; 182:167-174.
8. Rofsky NM, Weinreb JC, Bernardino ME, Young SW, Lee JK, Noz ME. Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging. Radiology 1993; 188:53-59.
9. Vogl TJ, Hamm B, Schnell B, et al. Mn-DPDP enhancement patterns of hepatocellular lesions on MR images. JMRI 1993; 3:51-58.
10. Liou J, Lee JKT, Borrello JA, Brown JJ. Differentiation of hepatomas from nonhepatomatous masses: use of MnDPDF-enhanced MR images. Magn Reson Imaging 1994; 12:71-79.
11. Sidhu MK, Muller HH, Aggeler J, Johes AL, Young SW. Manganese dipyridoxal diphosphate-enhanced magnetic resonance imaging in the evaluation of hepatocyte function. Invest Radiol 1993; 28:903-910.
12. Popper H. Pathologic aspects of cirrhosis: a review. Am J Pathol 1977, 87:228-264.
13. Dodd GD III, Miller WJ, Baron RL, Skolnik ML, Campbell WL. Detection of malignant tumors in end-stage cirrhotic livers: efficacy of sonography as a screening technique. AJR 1992; 159 727-733.
14. Miller WJ, Baron RL, Dodd GD III, Federle MP. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology 1994, 193:645-650.
15. Ohishi H, Uchida H, Yoshimura H, et al. Hepatocellular carcinoma detected by iodized oil: use of anticancer agents. Radiology 1985; 154:25-29
16. Dalke DD, Sorrell MF, Casey CA, Tuma DJ. Chronic ethanol administration impairs receptor-mediated endocytosis of epidermal growth factor by rat hepatocytes. Hepatology 1990; 12:1085-1091.
17. Wendt RE III, Wilcott MR III, Nitz W, Murphy PH, Bryan RN. MR imaging of susceptibility-induced magnetic field inhomogeneities Radiology 1988; 168:837-841.
18. Haacke EM, Tkach JA, Parrish TB. Reduction of T2* dephasing in gradient field-echo imaging. Radiology 1989; 170:457-462.
19. Murakami T, Kuroda C, Marukawa T, et al. Regenerating nodules in hepatic cirrhosis: MR findings with pathologic correlation. AJR 1990; 155:1227-1231.
20. Murakami T, Nakamura H, Hori S, et al. CT and MRI of siderotic regenerating nodules in hepatic cirrhosis. J Comput Assist Tomogr 1992; 16:578-582.
21. Ohromo K, Itai Y, Ohtomo Y, et al. Regenerating nodules of liver cirrhosis: MR imaging with pathologic correlation. AJR 1990; 154:505-507.
22. Ohtomo K, Baron RL, Dodd GD III, et al. Confluent hepatic fibrosis in advanced cirrhosis: appearance at CT. Radiology 1993, 188:31-35.
23. Ohtomo K, Baron RL, Dodd GD III, Federle MP, Ohtomo Y, Confer SR. Confluent hepatic fibrosis in advanced cirrhosis: evaluation with MR imaging. Radiology 1993; 189:871-874.
24. Kadoya M, Matsui O, Takashima T, Nonomura A Hepatocellular carcinoma: correlation of MR imaging and histologic findings Radiology 1992; 183:819-825.
25. Harbin WP, Robert NJ, Ferrucci JT Diagnosis of cirrhosis based on regional changes in hepatic morphology: a radiological and pathological analysis. Radiology 1980; 135: 273-283.
26. Van Beers B, Pringot J, Trigaux JP, et al. Hepatic heterogeneity on CT in Budd-Chiari syndrome: correlation with regional disturbances in portal flow. Gastrointest Radiol 1988; 13:61-66.
27. Starzl TE, Halgrimson CG, Francavilla FR, Porter KA, Brown TH, Putnam CW. The origin, hormonal nature and action of hepatotrophic substances in portal venous blood. Gynecol Obstet 1973; 137:179-199
28. Fischer B, Szuch P, Levine M, Saffer E, Fischer ER. The intestine as a source of a portal blood factor responsible for liver regeneration. Surg Gynecol Obstet 1973; 137:210-214.